UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-32371
SINOVAC BIOTECH LTD.
No. 39 Shangdi Xi Rd, Haidian District
Beijing 100085, People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
SINOVAC BIOTECH LTD. |
| |
|
|
| |
By: |
/s/ Nan Wang |
| |
Name: |
Nan Wang |
| |
Title: |
Chief Financial Officer |
Date: June 15, 2026
Exhibit Index
| Exhibit 99.1 |
| Press Release |
Exhibit 99.1
SINOVAC Regained Compliance With the Nasdaq Global Market’s
Listing Requirements
BEIJING, China June 15, 2026 – Sinovac Biotech Ltd. (Nasdaq:
SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that
it received a notification letter dated June 10, 2026 (the “Notification Letter”), from Hearing Advisor of The Nasdaq Stock
Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance
with the Nasdaq Global Market’s listing requirements. As noted in the Hearing Panel’s May 20, 2026 compliance determination, the Company
remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027.
The Company filed its annual report on Form 20-F
for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel,
applied for by the Company, had accordingly been canceled.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical
company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development,
manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The Company’s diversified portfolio includes vaccines for influenza,
viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified
by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella
vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious
disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and
COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu®),
the world’s first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19
vaccine globally.
Beyond its marketed portfolio, the Company is advancing a robust pipeline
that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC
is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners.
Through broader market presence, technological cooperation, and localized production, the Company aims to accelerate vaccine development
and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for
future pandemics.
For more information, please see the Company’s website at www.sinovac.com.cn
or www.sinovac.com.
Contacts
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279 9779
Email: ir@sinovac.com
